

April 30, 2025

BSE Limited	Code: 532321	National Stock Exchange of India Limited
		Code: Zyduslife
P J Towers,		Exchange Plaza, C/1, Block G, Bandra-Kurla
Dalal Street,		Complex, Bandra (East),
<u>Mumbai-400001</u>		Mumbai-400051

Re.: Appointment of a Senior Management Personnel

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Circular dated December 31, 2024 ("SEBI Circular")

Dear Sir / Madam,

This is to inform that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of Zydus Lifesciences Limited have approved the appointment of Mr. Tushar Shroff as a President-Finance, who shall form part of the Senior Management Personnel.

Necessary details as stipulated under regulation 30 of the Listing Regulations read with para 7 of Part A of the SEBI Circular are provided in **Annexure-"1"**.

Please find the same in order.

Thanking you,

Yours faithfully, For, **Zydus Lifesciences Limited**

Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063

Encl.: As above





Annexure-"1"

Sr. No.	Particulars	Responses
1.	Name	Mr. Tushar Shroff
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	The Company intends to strengthen its finance team in view of the increase in business operations and the complexity of its business. Taking into consideration the above, Mr. Tushar Shroff is appointed as a President-Finance, who shall
		form part of the Senior Management Personnel.
3.	Date of appointment / re- appointment / cessation (as applicable) & term of appointment / re- appointment;	Date of appointment: April 30, 2025 Term of appointment: full time employment
4.	Brief profile (in case of appointment)	Accountant and a Cost Accountant. He has 29+ years' post qualification experience, out of which 20 years' experience is in pharma industry. In pharma industry, he has experience in managing pharmaceutical life cycle of small, large molecules, blood products, from innovation to late life cycle development of generic, branded generic, CDMO and OTC business for USA, EU, and pharma emerging markets.
		Out of 29 years, he has 15+ years' experience as a chief financial officer. He has domain knowledge in the areas of business partnering, operational finance, corporate finance, mergers and acquisitions, divestures, in / out licensing, treasury management and fund raising, investor relations, strategic finance



		(structuring and re-organisation), legal, secretarial and information technology.
		Amongst others, he has worked with ABB Limited, Piramal Healthcare Limited and Intas Pharmaceuticals Limited. He had also worked with Zydus Lifesciences Limited from December 2010 to January 2019. Before joining Zydus, he was the Chief Financial Officer at Sterlite Technologies Limited.
5.	Disclosure of relationship between directors (in case of appointment of a director)	Not applicable

For, Zydus Lifesciences Limited

Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063